Business
Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference
SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, July 29th, 2025 at 9:20 a.m. ET. The live webcast will be available on Connect’s website in the Investor
About this update from Connect Biopharma Holdings Limited
[{"type":"image","alt":"Connect Biopharma Holdings Limited","displaySize":"","headline":null,"caption":"Connect Biopharma Holdings Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":83,"url":"https://media.zenfs.com/en/globenewswire.com/f3a290cabae4a8e314429e2a9e477131"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/d9Dv0E8EdrX1flrzOZWuxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f3a290cabae4a8e314429e2a9e477131","width":300,"height":83}},"lazy":false},{"type":"text","content":"SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, July 29th, 2025 at 9:20 a.m. ET.","length":428,"tagName":"p"},{"type":"text","content":"The live webcast will be available on Connect’s website in the Investors section under Presentations, Events & News at investors.connectbiopharm.com. An archived replay will be available for approximately 90 days following the event.","length":243,"tagName":"p"},{"type":"text","content":"About Connect BiopharmaConnect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect also has an exclusive license and collaboration agreement for rademikibart with Simcere in China.","length":577,"tagName":"p"},{"type":"text","content":"For more information visit www.connectbiopharm.com.","length":56,"tagName":"p"},{"type":"text","content":"Forward-Looking StatementsThis press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended (the “Act”). Forward-looking statements are statements that are not of historical fact and include, without limitati...